A 29-year-old woman with complex atypical hyperplasia and polycystic ovary syndrome: a challenging issue

Background: The standard treatment for complex atypical hyperplasia is hysterectomy and bilateral salpingo-oophorectomy. Although radical surgery offers high survival prospects, it also eliminates any chance of further fertility, thus in young nulliparous women who wish to preserve their childbearing potential, a conservative progestin therapy is preferable. Case report: The authors report a case of complex atypical hyperplasia in a 29-year-old nulliparous woman with polycystic ovary syndrome treated with norethisterone acetate in order to preserve her childbearing potential. The specimens sampled during the follow-up demonstrated inactive endometrium with pseudodecidual changes and no ultrasonographic images exhibited abnormal endometrial thickness. Conclusion: According to literature and to the authors’ experience, they can affirm that progestin treatment is the most reasonable option for young nulliparous women affected by complex atypical hyperplasia who desire to maintain their fertility potential, showing its efficacy also in patients with an associated polycystic ovary syndrome.

Complex atypical hyperplasia; Uterus-sparing management; Norethisterone acetate; Young woman; Polycystic ovary syn-drome.

[1] Gadducci A., Spirito N., Baroni E., Tana R., Genazzani A.R.: “The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option”. Gynecol. Endocrinol., 2009, 25, 683.

[2] Reed S.D., Voigt L.F., Newton K.M., Garcia R.H., Allison H.K., Epplein M. et al.: “Progestin therapy of complex endometrial hyperplasia with and without atypia”. Obstet. Gynecol., 2009, 113, 655.

[3] Baker J., Obermair A., Gebski V., Janda M.: “Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature”. Gynecol. Oncol., 2012, 125, 263.

[4] Sherman M.E.: “Theories of endometrial carcinogenesis: a multi-disciplinary approach”. Mod. Pathol., 2001, 13, 295.

[5] Corrado G., Baiocco E., Carosi M., Vizza E.: “Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report”. Fertil. Steril., 2008, 90, 2006.

[6] Epplein M., Reed S.D., Voigt L.F., Newton K.M., Holt V.L., Weiss N. S.: “Endometrial hyperplasia risk in relation to recent use; of oral contraceptives and hormone therapy”. Ann. Epidemiol., 2009, 19, 1.

[7] Ricciardi E., Maniglio P., Frega A., Marci R., Caserta D., Moscarini M.: “Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view”. Eur. Rev. Med. Pharmacol., 2012, 16, 1934.

[8] Ercan C.M., Duru N.K., Sakinci M., Alanbay I., Karasahin K.E., Baser I.: “Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system”. Gynecol. Endocrinol., 2010, 26, 125.

[9] Morelli M., Di Cello A., Venturella R., Mocciaro R., D’Alessandro P., Zullo F.: “Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women”. Gynecol. Endocrinol., 2013, 29, 156. [23]

[10] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review”. Gynecol. Oncol., 2012, 125, 477.

[11] Trimble C.L., Method M., Leitao M., Lu K., Ioffe O., Hampton M. et al.: “Management of endometrial precancers”. Obstet. Gynecol., 2012, 120, 1160.

[12] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: “Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis”. Am. J. Obstet. Gynecol., 2012, 207, 266.

[13] Reed S.D., Newton K.M., Garcia R.L., Allison K.H., Voigt L.F., Jordan C.D. et al.: “Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy”. Obstet. Gynecol., 2010, 116, 365.

[14] Han A.R., Kwon Y.S., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T. et al.: “Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia”. Int. J. Gynecol. Cancer, 2009, 19, 147.

[15] Jobo T., Kawaguchi M., Imai M., Kuramoto H.: “Treatment for complex atypical hyperplasia of the endometrium”. Eur. J. Gynaecol. Oncol., 2001, 22, 365.

[16] Karimi- Zarchi M., Mousavi A.S., Behtash N., Chiti Z., Bokaie M.: “Conservative management of young women with endometrial carcinoma or complex atypical hyperplasia: report of three cases and literature review”. Eur. J. Gynaecol. Oncol., 2011, 32, 695.

[17] Yasuda M., Matsui N., Kajiwara H., Osamura R.Y., Miyamoto T. et al.: “Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germcell tumor-like differentiation”. Pathol. Int., 2004, 54, 451.

[18] Rubatt J.M., Slomovitz B.M., Burke T.W., Broaddus R.R.: “Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia”. Gynecol. Oncol., 2005, 99, 472.

[19] Minig L., Franchi D., Boveri S., Casadio C., Bocciolone L., Sideri M.: “Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women”. Ann. Oncol., 2011, 22, 643.